Oculis Holding AG (NASDAQ:OCS) Receives Average Recommendation of “Buy” from Brokerages (2024)

Posted by MarketBeat News on Jun 23rd, 2024

Oculis Holding AG (NASDAQ:OCS – Get Free Report) has been given an average recommendation of “Buy” by the six research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have covered the stock in the last year is $30.17.

A number of equities research analysts have issued reports on OCS shares. Bank of America cut their price target on shares of Oculis from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, June 11th. Chardan Capital reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a report on Tuesday, June 11th. Robert W. Baird raised their price target on shares of Oculis from $35.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, June 11th. HC Wainwright raised their price target on shares of Oculis from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, June 11th. Finally, Wedbush reissued an “outperform” rating and issued a $29.00 price target on shares of Oculis in a report on Wednesday, March 6th.

View Our Latest Stock Report on OCS

Oculis Price Performance

Want More Great Investing Ideas?

OCS opened at $11.70 on Friday. The company has a 50 day moving average of $12.04 and a 200 day moving average of $11.83. The company has a market cap of $473.85 million, a PE ratio of -6.57 and a beta of 0.30. Oculis has a 12 month low of $9.05 and a 12 month high of $14.50. The company has a current ratio of 4.71, a quick ratio of 4.71 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS – Get Free Report) last posted its earnings results on Wednesday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.03). Oculis had a negative return on equity of 52.72% and a negative net margin of 6,712.02%. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, sell-side analysts expect that Oculis will post -1.9 EPS for the current year.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Searle & CO. purchased a new stake in Oculis during the 4th quarter worth approximately $112,000. Compagnie Lombard Odier SCmA grew its position in Oculis by 47.3% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock worth $1,053,000 after purchasing an additional 30,750 shares during the last quarter. Finally, abrdn plc purchased a new stake in Oculis during the 4th quarter worth approximately $15,980,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

(Get Free Report

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.